[Fluvastatin in patients after heart transplantation].
Hyperlipoproteinaemia is one of the frequent posttransplantation problems. Administration of statins is complicated in patients after transplantation by concurrent imunosuppressive treatment, in particular by possible undesirable interaction with cyclosporin. In the presented study 15 patients after transplantation of the heart with hyperlipoproteinaemia were examined who were on a standard triple combination of immunosuppressive drugs. Fluvastatin was administered, 20 mg in the evening, and in intervals of 6 weeks, 3 months and 6 months after the onset of treatment the levels of cholesterol, LDL and HDL-cholesterol, triglycerides, urea, creatinine, liver terts and cyclosporine were followed up. The mean cholesterol level declined from 7.66 mmol/l during the 6rd week (p < 0.002), to 6.01 mmol/l during 3rd month and to 5.83 mol/l after the 6rd month (p < 0.001), LDL-cholesterol declined from 4.82 mmol/l and then 3.46 mmol/l and 3.31 mmol/l (p < 0.001). In the other investigated parameters no change recorded, incl. the cyclosporin levels. No clinical signs of muscular damage were recorded Fluvastatin thus does not only reduce effectively the cholesterol and LDL-cholesterol level but is also safe combination with immunosuppressive treatment.
Spinarová
L
L
I. interní kardio-angiologická klinika Nemocnice U sv. Anny, Brno.
Toman
J
J
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D000077340:Fluvastatin; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D000077340:Fluvastatin